News11/12/2021
NewLimit announces formation
NewLimit, Inc. →Brian Armstrong and Blake Byers announced the formation of NewLimit to develop therapies based on epigenetic reprogramming. The company described a for-profit drug-development mission focused on extending human healthspan.